Cannabis Law Report

JULY 24, 2021

The groundbreaking progress that we’ve seen from the Multidisciplinary Association for Psychedelic Studies (MAPS) in its Phase 3 clinical trials of MDMA-assisted psychotherapy for Post-Traumatic Stress Disorder (PTSD), including receiving Breakthrough Therapy Designation from the Food and Drug Administration (FDA), shows great promise to date.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

Cannabis Law Report

AUGUST 3, 2021

Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

MMJ Recs

JULY 30, 2024

Post-Traumatic Stress Disorder (PTSD) is a multifaceted mental health condition triggered by experiencing or witnessing traumatic events, persistently manifesting in symptoms like flashbacks, severe anxiety, and disrupted sleep. Need more information about medical marijuana as a treatment? Check it out today for additional information!

Therapy 116

Therapy Treatment Clinical Trials Sleep 116

The Cannigma

MARCH 25, 2021

It is also crucial so that the correct data is collected in order to inform further research and clinical trials that are necessary for cannabis medicines to reach the UK National Health Service. The idea behind the MDT series is to place the unfamiliar cannabis medicines into a familiar case discussion format.

Patients 145

Patients Clinical Trials Medicine Events 145

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 40

Clinical Trials Pharmaceutical Cannabinoids Data 40

Puff Puff Post

NOVEMBER 5, 2019

5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. VANCOUVER, Nov.

Clinical Trials 8

Clinical Trials Pharmaceutical Cannabinoids Data 8

Cannabis Law Report

JUNE 17, 2021

Brains is one of a few companies in the world producing CBD as an API for pharmaceutical applications, research, development, and clinical trials. More information can be found at www.dsm.com/venturing. Readers should not place undue reliance on the forward-looking statements and information contained in this news release.

Pharmaceutical 105

Pharmaceutical Clinical Trials Research and Development Events 105

Cannabis Law Report

JULY 29, 2021

For more information visit: www.tetrabiopharma.com. Some statements in this release may contain forward-looking information. Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.

Research and Development 105

Research and Development Clinical Trials Events Cannabinoids 105

Veriheal

JUNE 30, 2023

For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial. The 13 individuals were chosen because of their reported improvements in negative drinking behavior following the clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Puff Puff Post

MARCH 10, 2020

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers. For more information, visit www.inmedpharma.com.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

JULY 28, 2021

The Company and Its Subsidiary KGK Science Have Also Completed the Pre-Qualification Audits of Its Canadian Facilities to Enable Clinical Trials in an Arrangement with Aleafia Health. The audits will enable KGK to conduct clinical trials in the areas of psychedelics and nutraceuticals, among other substances of study.

Clinical Trials 81

Clinical Trials Research and Development Treatment Therapy 81

Cannabis Law Report

AUGUST 17, 2021

Ganaxolone was generally well-tolerated with somnolence reported as the most common adverse event, consistent with previous trials; in addition, one treatment-related serious adverse event of seizure was reported in the trial. For more information visit www.marinuspharma.com. Conference Call and Webcast Details.

Pharmaceutical 76

Pharmaceutical Clinical Trials Treatment Patients 76

Cannabis Law Report

OCTOBER 6, 2021

(NASDAQ: FLGC) (“Flora” or the “Company”), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, is pleased to announce that it has signed an agreement to begin scientific clinical trials globally. or follow @floragrowthcorp on social for more information. Visit www.floragrowth.ca

Clinical Trials 40

Clinical Trials Research and Development Pharmaceutical Events 40

Cannabis Law Report

SEPTEMBER 9, 2021

Investors may register for the conference at the event website. The live and archived webcast will be available for 90 days after the event. Supera-CBD is being developed to address anxiety, chronic pain, addiction, and seizures, and is on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain.

Pharmaceutical 74

Pharmaceutical Clinical Trials Chronic Pain Epilepsy 74

Puff Puff Post

SEPTEMBER 16, 2019

.” As Québec’s first and foremost medical cannabis clinic and research centre, Santé Cannabis has received referrals from more than 2,500 physicians and assessed over 6,000 patients since 2014, while also providing information sessions for patients and healthcare professionals. Time: 9:00AM to 5:00PM.

Programs 108

Programs Research and Development Education Treatment 108

Cannabis Law Report

AUGUST 12, 2021

Phase IIb clinical trial of COMP360 psilocybin therapy for TRD close to completion. Availability of other information about COMPASS Pathways. The information that we post on these channels and websites could be deemed to be material information. Business highlights. On track to report top-line data by end of 2021.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Veriheal

MAY 3, 2022

Clinical Trial Sample Size. The trial was conducted with just 186 participants, which is far too small of a sample size to provide findings generalizable to the larger population. Missing Information. While lengthy, there is a surprising amount of missing information in the study.

Research and Development 98

Research and Development Clinical Trials Consumption Patients 98

Cannabis Law Report

DECEMBER 20, 2021

(“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., For more information, please visit www.virpaxpharma.com. About Altasciences. Christopher M.

Clinical Trials 40

Clinical Trials Chronic Pain Pharmaceutical Data 40

Project CBD

MAY 3, 2023

Dr. Goldstein: We don’t have clinical trials to say, yes this is definitively beneficial or detrimental for children. But we may be on the cusp of having those trials, which would be very exciting. It’s really a full day with lots of information for anyone who wants to advance their knowledge. I really enjoy it.

Cannabinoids 213

Cannabinoids Sleep Clinical Trials CBD 213

Puff Puff Post

JULY 8, 2019

She is a seven-time Olympic trials qualifier in three sports: marathon (three), triathlon (three), and swimming (one). When she is not training for running events, Dr. Zeiger works as a cannabis epidemiologist. Our results need to be replicated in larger studies and clinical trials. About Canna Research Group.

Chronic Pain 109

Chronic Pain Research and Development Clinical Trials THC 109

Cannabis Law Report

JULY 29, 2021

of their dry weight and it is not practical to obtain meaningful pure amounts of these compounds from the flesh of mushrooms, at a reasonable cost, to conduct clinical trials in humans and to commercialize these products. The information contained within the DMF may be used to support an Investigational New Drug (IND) application.

Clinical Trials 105

Clinical Trials Conditions Packaging Events 105

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. For more information, visit www.mymd.com. in the blood.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Therapy 40

Cannabis Law Report

JULY 28, 2021

We look forward to providing continued updates on our intellectual property, research, clinical, regulatory and manufacturing activities for PD-001; our novel oral formulation of cepharanthine, with the aim of working towards a first-in-human, proof-of-concept clinical trial under an FDA IND approval.” ” Next Steps.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Puff Puff Post

JULY 8, 2019

She is a seven-time Olympic trials qualifier in three sports: marathon (three), triathlon (three), and swimming (one). When she is not training for running events, Dr. Zeiger works as a cannabis epidemiologist. Our results need to be replicated in larger studies and clinical trials. About Canna Research Group.

Chronic Pain 108

Chronic Pain Research and Development Clinical Trials THC 108

Cannabis Law Report

AUGUST 2, 2021

(OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. Logo – [link]. SOURCE SciSparc Ltd.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

Cannabis Law Report

JUNE 4, 2021

Clinical trial information: NCT03276572 ( [link] ). While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. Abstract Number: 5015.

Data 100

Data Research and Development Clinical Trials Therapy 100

Cannabis Law Report

JUNE 7, 2021

For more information on the Russell Microcap® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website. For more information, visit www.mymd.com. For more information, visit www.ftserussell.com. Approximately $10.6 About MyMD Pharmaceuticals, Inc. About FTSE Russell.

Pharmaceutical 79

Pharmaceutical Clinical Trials CBD Banking 79

Cannabis Law Report

NOVEMBER 12, 2021

In the event that the Maximum LTV is exceeded, Brown Shipley can make a call on the Guarantors requiring them to place cash with Brown Shipley for the aggregate amount of the excess exposure over the Maximum LTV. OCT is conducting pre-clinical testing and development with pre-clinical trials scheduled for 2022.

Cannabinoids 98

Cannabinoids Clinical Trials Research and Development Pharmaceutical 98

Cannabis Law Report

NOVEMBER 19, 2021

“These additional patent filings are key as PsyBio moves towards the initiation of appropriately approved safety and efficacy clinical trials for our selected compounds within the production and manufacturing arena, for the Company as well as for our investors.”

Clinical Trials 52

Clinical Trials Research and Development Events Safety 52

Cannabis Law Report

AUGUST 25, 2021

“Lucid has successfully developed a strong pipeline of novel therapeutic compounds — supported by IP in order to advance to future clinical trials — and we are confident that the experience the Lucid leadership team brings will allow us to immediately start the process towards clinical trials to further advance these promising therapies.

Clinical Trials 85

Clinical Trials Research and Development Therapy Conditions 85

Cannabis Law Report

JULY 27, 2021

Research opportunities such as the ORR expand the existing scientific knowledge base to better inform clinical decision making, and also dispels the stigma surrounding medicinal cannabis use.”. plan to conduct a controlled clinical trial to further understand the effects of CBD in epilepsy treatment.

Data 81

Data Epilepsy Research and Development Clinical Trials 81

Cannabis Law Report

JUNE 8, 2021

This SRA will leverage four other clinical trials being planned by the university, to determine the effects of psilocybin on inflammatory markers of patients who have exhibited Parkinson’s, Bipolar disorder, and chronic back pain. For more information, visit www.silopharma.com. Safe Harbor and Forward-Looking Statements.

Patients 70

Patients Research and Development Clinical Trials Chronic Pain 70

Cannabis Law Report

OCTOBER 28, 2021

Psymposia report… O n Sep 23, 2021, Psymposia staff received an email from the personal email account of Mark Haden — the former Executive Director of psychedelic nonprofit MAPS Canada and current Director of Clinical Trials for Psygen Inc.

Data 52

Data Clinical Trials Events Medicine 52

Cannabis Law Report

JULY 9, 2021

The prospectus contains important detailed information about the ETF. Clinical trials involving psychedelic drugs and substances are, however, permitted, provided they comply with both state and federal laws applicable to such trials. Please read the prospectus before investing.

Data 105

Data Clinical Trials Decriminalization Hemp 105

Cannabis Law Report

JUNE 15, 2021

Brains is one of a few companies in the world producing CBD as an API for pharmaceutical applications, research, development, and clinical trials. More information can be found at www.dsm.com/venturing. Readers should not place undue reliance on the forward-looking statements and information contained in this news release.

Pharmaceutical 63

Pharmaceutical Clinical Trials Research and Development Events 63

Cannabis Law Report

JULY 7, 2021

BioMAP Diversity PLUS informs a drug candidate’s potency, selectivity, safety, mechanism of action and disease indication. Additionally, these findings can provide actionable insights to help progress the right molecules to further clinical testing. For more information, visit www.mymd.com. Eurofins is testing for life.

Pharmaceutical 81

Pharmaceutical Data Clinical Trials Research and Development 81

Cannabis Law Report

JANUARY 12, 2022

“This is a landmark event for Gb Sciences,” said Chairman and CEO John Poss. “We can now concentrate all our energies on advancing our plant-inspired, biopharmaceutical research and development programs into human clinical trials.” Andrea Small-Howard, President and Chief Science Officer of Gb Sciences.

Research and Development 52

Research and Development Clinical Trials Chronic Pain Therapy 52